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Key messages
 ► This trial, assessing the efficacy and safety of pir-
fenidone in patients with fibrosing uILD, will be the 
first controlled study assessing a potential treatment 
option solely in this population.
 ► The study design has considered the definition of 
uILD, current treatment practice in uILD and the 
most appropriate measurements of treatment effi-
cacy in this population.
 ► It is hoped that these methodological considerations 
will allow meaningful clinical data to be generated 
that would inform treatment strategies and improve 
outcomes for patients with fibrotic uILD.
AbstrAct
Introduction Despite extensive multidisciplinary team 
(MDT) assessment, some patients have interstitial lung 
disease (ILD) that is considered unclassifiable (uILD), for 
which there are currently no approved treatments. This 
study will assess the efficacy and safety of the antifibrotic 
pirfenidone in treating uILD.
Methods and analysis This double-blind, randomised, 
placebo-controlled phase II trial is enrolling adults with 
fibrosing ILD, including uILD that fulfils proposed research 
criteria for interstitial pneumonia with autoimmune 
features (IPAF), that cannot be classified with moderate 
or high confidence to any category of ILD following MDT 
discussion. Study participants must have >10% fibrosis 
on high-resolution CT scan within the previous 12 months, 
forced vital capacity (FVC) ≥45% and diffusing capacity of 
the lung for carbon monoxide ≥30% of predicted values. 
Study participants will be randomised to receive 801 mg 
pirfenidone or placebo three times daily for 24 weeks. The 
efficacy of pirfenidone vs placebo will be assessed by daily 
measurement of FVC using a handheld spirometer over 
the treatment period. Other functional parameters, patient-
reported outcomes, samples for biomarker analysis and 
safety endpoints will be collected. Additionally, the study 
will assess the efficacy and safety of pirfenidone with and 
without concomitant mycophenolate mofetil treatment and 
in study participants with or without IPAF.
Ethics and dissemination This trial is being conducted 
in accordance with the International Conference on 
Harmonisation E6 guideline for Good Clinical Practice, 
Declaration of Helsinki and local laws for countries in 
which the research is conducted.
trial registration number NCT03099187.
IntroductIon
Interstitial lung disease (ILD) comprises 
a large group of diseases characterised 
by inflammation or fibrosis of pulmonary 
tissue.1 2 ILDs can be caused by environmental 
exposures or may be secondary to another 
condition, such as connective tissue disease 
(CTD) or sarcoidosis; alternatively, ILDs may 
not have a clear predisposing factor (idio-
pathic interstitial pneumonias (IIPs)).1 2 Idio-
pathic pulmonary fibrosis (IPF) is the most 
common IIP.3 Other IIPs include idiopathic 
non-specific interstitial pneumonia, respira-
tory bronchiolitis-ILD, desquamative inter-
stitial pneumonia, cryptogenic organising 
pneumonia, acute interstitial pneumonia and 
some rare forms of IIP.2 4 
However, 4%–24% of patients with ILD 
cannot be given a specific diagnosis, even 
after thorough investigation by a multidisci-
plinary team (MDT)5–11; in these cases, the 
disease is considered an ‘unclassifiable ILD’ 
(uILD).1–4 12 An ILD might be labelled unclas-
sifiable for various reasons, including a lack 
of biopsy, an inadequate or non-diagnostic 
biopsy and/or major discrepancies between 
clinical, radiological and pathological find-
ings.1 3 Therefore, uILD represents a hetero-
geneous collection of undiagnosed ILDs with 
patients displaying clinical features of IPF 
and other non-IPF ILDs.5 Diagnosis of uILD 
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Treatment period
Weeks 1 to 24
Enrolment and
randomisation:
titration period followed by
daily dose of 2403 mg/day








Weeks –7 to –3
ICF† ICF†
Figure 1 Study design. *Washout period for study participants taking prohibited medications prior to screening; patients not 
taking a prohibited medication will forgo the washout period and directly enter screening. †Informed consent may be obtained 
either at the washout (if applicable) or screening visits and must be obtained before any trial-specific screening procedure is 
performed. ‡After completion of the treatment period and follow-up visit, study participants will be given the opportunity to 
take part in an open-label extension of pirfenidone for up to 12 months; a final follow-up visit will be performed 4 weeks after 
the last open-label dose of pirfenidone. ICF, informed consent form.
is associated with survival rates and disease progression 
that are either intermediate between those associated 
with IPF and non-IPF ILD or similar to those of non-IPF 
ILD.5 11
Interstitial pneumonia with autoimmune features 
(IPAF) is a specific research classification scheme that 
clinically remains within the category of uILD because, 
although a variety of clinical, serological or pulmonary 
morphological autoimmune features may be identi-
fied, individuals with IPAF do not have a characterisable 
CTD.13 An estimated 7% of patients with ILD have IPAF14; 
these patients cannot be diagnosed with a specific type of 
IIP or CTD-ILD13 and seem to have similar or marginally 
better survival rates than patients with IPF.14 15
Determining treatment strategies for patients with 
features of multiple diagnoses, such as those with IPF or 
chronic hypersensitivity pneumonitis,1 13 can be particu-
larly challenging, as immunosuppressive or antifibrotic 
approaches are both possible options.1 Although there 
have been no controlled clinical trials in patients with 
uILD and no pharmacological treatments are approved 
for the treatment of these populations, data have been 
published on the treatment of specific patients with uILD 
with immunosuppressive therapies and/or corticoste-
roids, which were generally associated with good initial 
responses to treatment.16–18 Clinical trials have demon-
strated that the antifibrotic drugs pirfenidone and 
nintedanib reduce disease progression in patients with 
IPF, and both are approved for the treatment of IPF.19–21
Given the overlap between clinical, radiological and 
histopathological features of IPF and uILD, antifibrotic 
therapy may be beneficial in patients with uILD, particu-
larly in cases characterised by considerable fibrosis. The 
current double-blind, randomised, placebo-controlled 
phase II trial therefore aims to evaluate the efficacy and 
safety of pirfenidone in patients with fibrosing uILD, 




This is a multicentre, international, double-blind, 
two-arm, randomised, placebo-controlled phase II trial 
( Clinicaltrials. gov: NCT03099187) that plans to enrol 
approximately 250 patients across 60 clinical centres in 
Australia, Canada, Europe and Israel (for details of study 
sites visit: https:// clinicaltrials. gov/ ct2/ show/ study/ 
NCT03099187). Patient enrolment began in April 2017. 
The trial will evaluate the efficacy and safety of pirfeni-
done in study participants over 24 weeks (figure 1). 
Study data will be managed according to the procedures 
described in online supplementary appendix 1.
study participants
Patients aged ≥18–85 years with fibrosing uILD will be 
eligible for recruitment into this study. This trial is being 
conducted in accordance with the International Confer-
ence on Harmonisation E6 guideline for Good Clin-
ical Practice and the principles of the Declaration of 
Helsinki, or the laws and regulations of the countries in 
which the research is conducted, whichever affords the 
greater protection to the individual. Informed consent 
will be obtained from each patient by the study investi-
gator before any trial-specific screening procedure is 
performed. Fibrosing uILD will be defined as cases of 
fibrosing ILD that cannot be classified with moderate 
or high confidence to any category of ILD after MDT 
discussion. Levels of confidence in a diagnosis will be 
defined as follows: (1) high: a specific diagnosis is highly 
likely; (2) moderate: the MDT arrives at a working diag-
nosis of a particular ILD that is sufficient to lead to a 
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Figure 2 Patient case study 1—chronic fibrosing ILD 
in the setting of IPAF. CCP, cyclic citrullinated peptide; 
DLco, diffusing capacity of the lung for carbon monoxide; 
FVC, forced vital capacity; HRCT, high-resolution CT; IIP, 
interstitial pneumonia; ILD, interstitial lung disease; IPAF, 
interstitial pneumonia with autoimmune features; MDT, 
multidisciplinary team; UIP, usual interstitial pneumonia.
Figure 3 Patient case study 2—fibrotic uILD in the setting 
of IPAF. CTD, connective tissue disease; DLco, diffusing 
capacity of the lung for carbon monoxide; FVC, forced 
vital capacity; HRCT, high-resolution CT; ILD, interstitial 
lung disease; IPAF, interstitial pneumonia with autoimmune 
features; IPF, idiopathic pulmonary fibrosis; MDT, 
multidisciplinary team; uILD, unclassifiable interstitial lung 
disease; UIP, usual interstitial pneumonia.
specific therapeutic strategy; (3) low: the MDT may have 
a suspicion of a particular ILD but considers the available 
evidence insufficient (ie, <50% likelihood22) to inform 
therapeutic strategy. The MDT at each centre will use all 
available clinical (comprising medical history including 
prior exposures, physical examination, pulmonary func-
tion and exercise capacity tests and so on), radiological 
and pathological evidence to attempt to diagnose study 
participants with a category of fibrosing ILD and may 
involve rheumatology expertise at their discretion. If a 
surgical lung biopsy or transbronchial lung cryobiopsy 
was not undertaken to provide evidence for a specific 
diagnosis, the investigator should state the reason why 
this was the case. Study participants with uILD who fulfil 
proposed research classification criteria for IPAF13 will be 
eligible for inclusion. Study participants will be excluded 
from this study if IPF is the main differential or working 
diagnosis, irrespective of confidence level in the diag-
nosis. Examples of the types of patients who could be 
enrolled in this study can be found in the patient case 
studies (figures 2–4).
Eligible participants must have >10% extent of fibrosis 
(eg, reticulation) on visual scoring of a high-resolution 
CT (HRCT) scan, as assessed by the thoracic radiologist at 
each centre, within the previous 12 months to be consid-
ered for the trial, with forced vital capacity (FVC) ≥45% 
and diffusing capacity of the lung for carbon monoxide 
(DLco) ≥30% of predicted values. Study participants must 
also have progressive disease defined as either absolute 
decline in per cent predicted FVC >5%23 or significant 
symptomatic worsening not due to cardiac, pulmonary, 
vascular or other causes (as determined by the investi-
gator) within the previous 6 months. Other inclusion and 
exclusion criteria for this study are listed in box 1.
study drug administration and blinding
Enrolled patients will be randomised on Day 1 of the 
study in a 1:1 ratio to receive 2403 mg/day pirfenidone 
or placebo. The randomisation process will be conducted 
using a validated interactive voice or web-based response 
system (IxRS). To prevent selection bias and allow 
subgroup comparison, randomisation will be stratified 
by use of concomitant mycophenolate mofetil (MMF; 
including mycophenolate sodium and mycophenolic 
acid) and presence or absence of IPAF.
Pirfenidone will be administered orally in 267 mg 
capsules taken with food at the same times each day. 
The dose of pirfenidone will be titrated over 2 weeks 
from an initial dose of 801 mg/day during Week 1 (one 
capsule three times a day) to 1602 mg/day during Week 
2 (two capsules three times a day) to a maintenance 
dose of 2403 mg/day from Week 3 onwards (three 
capsules three times a day). The dose of pirfenidone 
used for each individual study participant will be at the 
discretion of the investigator. Temporary dose reduc-
tion, treatment interruption or discontinuation will 
be considered to manage treatment-emergent adverse 
events. Treatment will be discontinued in patients who 
become pregnant, experience hepatic or renal impair-
ment or angioedema or have substantial liver-function 
test elevations. Patients who are non-adherent with 
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Figure 4 Patient case study 3—low-confidence chronic 
hypersensitivity pneumonitis. DLco, diffusing capacity of 
the lung for carbon monoxide; FVC, forced vital capacity; 
HRCT, high-resolution CT; MDT, multidisciplinary team; 
uILD, unclassifiable interstitial lung disease.
box 1 Entry criteria
description of inclusion criteria
 ► Extent of fibrosis >10% on HRCT (visual scoring) within the last 12 
months.
 ► Spirometry criteria: FVC ≥45% predicted, DLco ≥30% predicted, 
FEV1/FVC ratio ≥0.7.
 ► 6MWD ≥150 m.
 ► Progressive disease: absolute decline in per cent predicted FVC 
>5% or significant symptomatic worsening not due to cardiac, pul-
monary, vascular or other causes in the previous 6 months.
 ► For women of childbearing potential: agreement to remain absti-
nent (refrain from heterosexual intercourse) or use a non-hormonal 
or hormonal contraceptive method with a failure rate of <1% per 
year during the treatment period and for at least 58 days after the 
last dose of trial treatment.
 ► For men: agreement to remain abstinent (refrain from heterosexual 
intercourse) or use contraceptive measures and agreement to re-
frain from donating sperm.
 ► Signed informed consent form and able to comply with the study 
protocol, according to the investigator’s judgement.
description of exclusion criteria
 ► Study participants previously treated with pirfenidone or nintedanib.
 ► Participation in a trial of an investigational medicinal product within 
the last 4 weeks.
 ► Drug treatment for any type of pulmonary hypertension (eg, silde-
nafil, ERA).
 ► Concomitant use of fluvoxamine.
 ► Significant coexistent emphysema (extent greater than extent of 
fibrosis on HRCT within the last 12 months).
 ► Clinical evidence of any active infection which, according to the 
investigator’s judgement, may interfere with trial conduct or mea-
surement of pulmonary function or impact the course of the ILD.
 ► History of unstable angina or myocardial infarction during the pre-
vious 6 months.
 ► An ECG with a heart-rate-corrected QT interval (corrected using 
QTcF) ≥500 ms at screening or a family or personal history of long 
QT syndrome.
 ► Any history of hepatic impairment, elevation of transaminase en-
zymes or the confirmation of any of the following liver-function test 
criteria above the specified limits:
 – Total bilirubin above the ULN.
 – AST or ALT >1.5 × ULN.
 – Alkaline phosphatase >2.0 × ULN.
 ► Creatinine clearance <30 mL/min, calculated using the Cockcroft-
Gault formula.
 ► Significant other-organ comorbidity, including hepatic or renal 
impairment.
 ► Any serious medical condition, clinically significant abnormality on 
an ECG at screening or laboratory test results (haematology, serum 
chemistry and urinalysis) which, in the opinion of the investigator, 
may pose an additional risk to the study participant following the 
administration of trial treatment.
 ► Planned major surgery during the trial.
 ► Predicted life expectancy <12 months or on an active transplant 
waiting list.
 ► Use of any tobacco product in the 12 weeks prior to the start of 
screening or any unwillingness to abstain from their use through to 
the follow-up visit.
Continued
their dosing regimen or titration schedule will be with-
drawn from the study.
To ensure blinding of the treatment group to investiga-
tors, study participants and the sponsor, study participants 
randomised to the placebo group will be administered 
placebo capsules with identical appearance, size and taste 
to pirfenidone capsules. If unblinding is necessary due 
to, for example, a serious adverse event, the study inves-
tigator will be able to reveal the patient’s allocated inter-
vention by contacting the IxRS.
concomitant therapies
Study participants who are receiving a stable dose of 
MMF for >3 months before screening and who are 
expected to remain on a stable dose of MMF, are 
eligible for inclusion in the trial. MMF has been used 
to successfully manage patients with a diverse range of 
ILDs (see Discussion section) and recruitment into the 
trial would be limited if concomitant MMF treatment 
was not permitted for patients receiving therapeutic 
benefit from this treatment. Use of other immuno-
suppressants is not permitted during the trial. Study 
participants may not receive treatment with high-dose 
systemic corticosteroids (ie, >15 mg/day prednisolone 
or equivalent) for >4 weeks during the trial. N-acetyl 
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box 2 Study endpoints
Primary endpoint
 ► Change in FVC (in mL) measured by daily home spirometry.
secondary endpoints
 ► Change in FVC (in mL and per cent predicted) measured by clin-
ic-based spirometry.
 ► Categorical change in FVC of >5% or >10% (absolute change in per 
cent predicted and relative change in mL), measured by both daily 
spirometry and spirometry during clinic visits.
 ► Change in per cent predicted DLco.
 ► Change in 6MWD.
 ► Change in UCSD-SOBQ score.
 ► Change in score in Leicester Cough Questionnaire.
 ► Change in cough visual analogue scale.
 ► Change in total and subscores of the SGRQ.
 ► Non-elective hospitalisation, both respiratory and all cause.
 ► Incidence of, and time to first, investigator-reported acute exac-
erbations (analogous to the criteria for acute exacerbation of IPF 
proposed by Collard et al24).
 ► PFS, defined as the time to the first occurrence of a >10% absolute 
decline in per cent predicted FVC (measured during a clinic visit), a 
>50 m decline of 6MWD or death.
 ► PFS, alternatively defined as the time to the first occurrence of 
a >10% relative decline in FVC (measured during a clinic visit), 
non-elective respiratory hospitalisation or death.
 ► Time to death from any cause.
 ► Time to death from respiratory diseases.
safety endpoints
 ► Nature, frequency, severity and timing of treatment-emergent ad-
verse events.
 ► Dose reductions and treatment interruptions.
 ► Clinical laboratory test results.
 ► 12-lead ECGs.
 ► Withdrawals from trial treatment or trial discontinuations.
6MWD, 6 min walk distance; DLco, diffusing capacity of the lung for carbon 
monoxide; FVC, forced vital capacity; IPF, idiopathic pulmonary fibrosis; PFS, 
progression-free survival; SGRQ, St. George's Respiratory Questionnaire; UCSD-
SOBQ, University of California–San Diego Shortness of Breath Questionnaire.
Box 1 Continued
 ► Illicit drug or alcohol abuse within 12 months prior to screening, 
according to the investigator’s judgement.
 ► Pregnant or lactating or intending to become pregnant during the 
trial.
 ► A positive urine pregnancy test, which was confirmed with a posi-
tive serum pregnancy test.
 ► Women of childbearing potential not using a reliable contraceptive 
method.
 ► Previous intolerance or allergy to the trial treatment.
 ► Hypersensitivity to the active substance or to any of the excipients 
of pirfenidone.
 ► History of angioedema.
6MWD, 6 min walk distance; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; DLco, diffusing capacity of the lung for carbon monoxide; 
ERA, endothelin receptor antagonist; FVC, forced vital capacity; FEV1, forced 
expiratory volume in 1 second; HRCT, high-resolution CT; ILD, interstitial lung 
disease; QTcF, Fridericia’s correction formula; QT, interval time between Q and T 
waves; ULN, upper limit of normal.
cysteine (NAC) is not permitted for the treatment of 
fibrotic lung disease within 4 weeks of the screening 
period; intermittent use of NAC for other conditions 
is permitted. Inhibitors or inducers of cytochrome 
P450 1A2 are not permitted during the trial due to the 
potential for drug interactions altering the exposure to 
pirfenidone. Study participants receiving prohibited 
medications will need to taper or discontinue these 
during the 4 weeks before screening (washout period).
study objectives and endpoints
The primary objective of this study is to evaluate the 
efficacy of pirfenidone vs placebo on FVC decline. This 
will be assessed by daily measurement of FVC using a 
handheld spirometer over the 24-week double-blind 
treatment period. Study participants will perform a 
single spirometry reading using a portable handheld 
Micro spirometer (CareFusion, Kent, England) at 
approximately the same time each day. Study partici-
pants will be given 60 min dedicated instruction on how 
to undertake spirometry at the screening visit. They will 
be asked to use the device during the screening period 
and will be subsequently retrained at the baseline visit, 
with additional refresher training provided after Month 
1, between Months 2 and 3 and between Months 4 and 
5. Measurements will be downloaded at each visit and 
patients with multiple missing values will be retrained 
either by the investigator at the centre or by a home 
nursing staff member on an additional visit.
The secondary objective is to evaluate the efficacy of 
pirfenidone vs placebo on other functional parameters and 
patient-reported outcomes (box 224). Clinic-based spirom-
etry will be conducted at baseline and then every 4 weeks 
until Week 24 (or the early treatment discontinuation visit). 
All other assessments (DLco, 6 min walk distance, Univer-
sity of California–San Diego Shortness of Breath Question-
naire, St. George's Respiratory Questionnaire and cough 
scores) will be conducted at baseline, Week 12 and Week 24 
(or the early treatment discontinuation visit).
The safety and tolerability of pirfenidone in this 
population will be assessed by collection of the nature, 
frequency, severity and timing of treatment-emergent 
adverse events. Information on dose reductions, treat-
ment interruptions and premature discontinuation of 
treatment will also be collected.
biomarker collection
To evaluate the impact of pirfenidone on potential 
inflammatory and fibrotic biomarkers associated with 
fibrosis and ILD, serum, plasma and whole blood will 
be collected from study participants at baseline, Week 4, 
Week 12 and Week 24 (or the early treatment discontin-
uation visit). Transcriptomic and proteomic profiling 
of markers associated with molecular pathways and 
copyright.
 on M











es: first published as 10.1136/bm






6 Maher TM, et al. BMJ Open Resp Res 2018;5:e000289. doi:10.1136/bmjresp-2018-000289
Open access
cellular processes of lung injury and fibrosis will be 
measured.
Research Biosample Repository (RBR) whole-blood 
samples for DNA extraction will also be collected at 
baseline to examine genetic polymorphisms and their 
potential role in the pathogenesis and associated clin-
ical outcomes of uILD. Specimens for the RBR will 
be collected from study participants who give specific 
consent to participate in this optional research. RBR 
specimens will be stored until they are no longer 
needed or until they are exhausted. The RBR storage 
period will be in accordance with informed consent and 
applicable laws, such as health authority requirements.
statistical analysis
The planned sample size of 250 patients is based on 
the statistical hypothesis of the primary endpoint and 
assumes 80% power and a two-sided α of 5% using a 
student’s t-test. After inspection of historical data, it is 
assumed that, over the course of the trial, FVC decline 
in the placebo arm will be 85 mL with a common SD of 
70 mL, which can be reduced to 60 mL with a common 
SD of 70 mL in the pirfenidone arm. In this scenario, 
125 patients per treatment arm are needed to detect 
this treatment effect with 80% power.
The primary endpoint will be analysed in a two-step 
approach: first, individual FVC decline for each patient 
will be estimated by applying a linear regression model 
to daily home spirometry measurements during the 
24-week treatment period. Second, mean FVC decline 
in each treatment arm, calculated using estimated FVC 
decline for each individual patient, will be compared 
using a student’s t-test with a two-sided significance 
level α=0.05. The primary analysis will be based on 
the intent-to-treat population; patients who discon-
tinue treatment prematurely will be analysed based on 
the available data and no imputation method will be 
applied for missing data. A linear mixed-effects model 
will be included as a sensitivity analysis to account for 
codependency of daily FVC measurements.
For the secondary endpoints, all data from baseline to 
Week 24 will be used without imputation, and p values 
will be reported in a descriptive fashion with no adjust-
ment for multiplicity (further details of statistical anal-
ysis of the secondary endpoints can be found in online 
supplementary appendix 2).
The safety analysis will include investigation of 
the nature, frequency, severity and timing of treat-
ment-emergent adverse events. The incidence, type 
and severity of adverse events will be summarised 
according to primary System Organ Class and subcat-
egorised by Medical Dictionary for Regulatory Activi-
ties version 19.1 preferred term. Adverse events Grade 
≥3 according to National Cancer Institute Common 
Terminology Criteria for Adverse Events V.4.0, adverse 
events of special interest (cases of potential drug-in-
duced liver injury) and serious adverse events will be 
analysed in a similar way to all adverse events. Descrip-
tive statistics will be presented for dose reductions and 
treatment interruptions, with adverse events leading to 
these occurrences summarised.
data Monitoring committee
There are no planned efficacy interim analyses for this trial; 
however, an independent Data Monitoring Committee 
(iDMC) will perform interim safety analyses and advise 
on trial conduct at least three times during the trial (6, 12 
and 18 months after the start of recruitment). Additional 
ad hoc meetings can be requested at any time by the iDMC 
or sponsor if necessary. The iDMC will be an independent 
body, unblinded to treatment allocation, who will recom-
mend that the study should be continued, modified or 
stopped during each meeting.
open-label extension study
All study participants will be offered the opportunity to 
receive open-label pirfenidone within the trial protocol 
during the follow-up visit at Week 28. In order to main-
tain blinding of the controlled period of the study, all 
study participants will discontinue treatment by Week 
24 and return for a follow-up visit 4 weeks later; study 
participants eligible to participate in the 12-month 
extension will be initiated on open-label pirfenidone 
during this visit (restarting the dose titration from 
one capsule three times a day). During the long-term 
extension period, study participants will be evaluated 
for safety endpoints only. Study participants should 
be evaluated by the investigator approximately every 
3 months during the 12-month safety follow-up (liver 
function tests will be measured monthly during the first 
6 months); a final follow-up visit will take place 4 weeks 
after the last dose of pirfenidone is taken.
dIscussIon
This study will be the first randomised controlled trial of 
an antifibrotic agent specifically in patients with uILD 
and aims to establish whether pirfenidone reduces 
the rate of FVC decline in this population. A study of 
nintedanib is underway in patients with progressive, 
‘physician-diagnosed fibrosing ILD’ including unclas-
sifiable IIP25; however, the study of pirfenidone is 
unique in that only patients with uILD will be included. 
A number of important methodological questions 
have been considered in the study design in order to 
generate meaningful clinical data and provide impor-
tant insights into treatment strategies for this patient 
population.
There is currently a lack of consensus on the defini-
tion of uILD, so the first key question in designing this 
trial was how best to properly identify patients with the 
greatest unmet need for inclusion in the study. In order 
to enrol patients for whom there is currently insufficient 
evidence available to inform a therapeutic strategy, 
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uILD will be defined as fibrosing ILD (>10% fibrosis on 
HRCT) that cannot be classified with moderate or high 
confidence to any category of ILD and that cannot be 
classified as IPF at any level of confidence. In patients 
with IPF, a decline in FVC of ≥10% over 12 months 
is generally taken to indicate progressive disease; 
however, FVC decline in patients with uILD is not well 
understood and therefore a threshold of 5% absolute 
decline (or significant symptomatic worsening, which 
would indicate later FVC decline) over 6 months was 
selected, the aim being to avoid restricting the eligible 
population of patients and to only exclude patients with 
very stable disease. Nevertheless, variability between 
FVC measurements is a potential limitation with a 5% 
threshold.
Importantly, diagnosis of uILD must be made by 
consensus following an MDT discussion. The use of 
MDTs in the diagnosis of IPF has improved the confi-
dence in diagnosis,26 and it is expected that making 
MDT discussion mandatory before the qualifying 
diagnosis of uILD can be made will ensure that study 
participants who can be diagnosed with a specific ILD 
are not included. Although the requirement for MDT 
discussion should reduce the chance that patients with 
a classifiable ILD are included in the study, it should be 
acknowledged that there may be differences in inter-
pretation between centres, particularly in those centres 
with a lower ILD case load. In an attempt to minimise 
this, training and case studies were provided at an 
investigator meeting. In addition, it could be argued 
that practice may vary between expert and non-expert 
centres with regard to assigning a diagnosis of IPF or 
other ILDs and the number of patients who could be 
classified as having uILD. Future diagnosis of uILD 
should ideally be made at an expert centre to avoid 
misclassification and allow for close monitoring of 
these patients.
One particular area of contention in defining uILD 
is whether a surgical lung biopsy should be mandatory 
before designating ILD as unclassifiable.1 12 22 It can 
be argued that uILD in patients who have not under-
gone a biopsy should be labelled ‘unclassified’ rather 
than ‘unclassifiable’, as a biopsy may have provided 
the necessary information for a diagnosis.1 Although a 
biopsy may provide critical diagnostic information in 
patients where a diagnosis cannot be made from HRCT 
and other clinical tests, this is not always possible due 
to medical risk or patient choice.1 12 Both surgical 
lung biopsy and transbronchial lung cryobiopsy were 
included as options in this study. Cryobiopsy has been 
shown to provide meaningful data to aid MDT diag-
nosis of ILD and is generally considered to be less inva-
sive than surgical lung biopsy.27 A diagnosis of uILD can 
be assigned regardless of whether a surgical lung biopsy 
has been performed, and the current study protocol 
does not specify which diagnostic tests should be 
conducted to make a diagnosis of uILD. The number 
of patients who undergo each procedure will be 
documented, and if a biopsy (either surgical biopsy or 
cryobiopsy) has not been conducted, then the protocol 
requests a reason to be given. Although inclusion of 
patients without biopsy data is a potential limitation, it 
does reflect clinical reality where many patients will not 
or cannot have a biopsy.
Another question relates to the inclusion of patients 
with uILD who fulfil research criteria for IPAF.13 
From a clinical diagnostic perspective, these patients 
remain unclassifiable and will therefore be included 
in the trial. However, assessment of treatment effect 
in patients with IPAF may be limited by heterogeneity. 
Therefore, randomisation will be stratified at baseline 
depending on whether a study participant meets IPAF 
research criteria, so that the effect of pirfenidone in 
these participants can be analysed separately.
Current treatment practice for patients with uILD 
is another important factor considered in the design 
of this trial. Although no therapies have been recom-
mended for treatment of patients with uILD, MMF 
has been used to successfully manage patients with a 
diverse range of ILDs in controlled clinical trials (in 
systemic sclerosis-related (SSc)-ILD)28 and obser-
vational studies (in CTD-ILD and IPAF)18 29 and is 
therefore a likely concomitant medication in patients 
screened for entry into this trial. The combination of 
pirfenidone and MMF has previously been studied in 
the phase II LOTUSS study of the safety and tolera-
bility of pirfenidone in patients with SSc-ILD.30 A total 
of 63.5% of patients in the LOTUSS trial received 
MMF and there were no clinically significant effects on 
overall tolerability compared with patients who did not 
receive MMF.30 Therefore, this study allows participants 
to receive concomitant MMF therapy during the treat-
ment period and, as in the LOTUSS trial, the effect of 
MMF on outcomes will be investigated by stratifying 
the population at randomisation based on whether 
or not they are receiving MMF at baseline. However, 
use of inhibitors or inducers of cytochrome P450 1A2, 
NAC for the treatment of fibrotic lung disease or other 
immunosuppressants besides MMF (eg, azathioprine or 
cyclophosphamide) will not be permitted in this study 
due to potential drug interactions or negative effects 
in combination with pirfenidone.28 29 31–33 The dose 
of pirfenidone (2403 mg/day) and initial dose titra-
tion used in this trial will be the same as the clinically 
recommended dose and titration used in patients with 
IPF.32 33 In the absence of any clinically approved treat-
ment for uILD, study participants in the control group 
will receive placebo during the 24-week double-blind 
treatment period.
Methods of assessing efficacy in the study population 
are another important consideration to ensure that 
meaningful clinical data are collected. Change in FVC 
is a generally accepted measure of disease course and 
a predictor of mortality risk in patients with ILD and 
has been examined in clinical studies that enrolled 
patients with uILD.5 34 The primary endpoint in this 
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trial will therefore assess rate of FVC decline. In 
order to ensure the 24-week treatment period is suffi-
cient to observe any clinically significant differences 
in FVC decline, FVC will be measured daily by study 
participants using a handheld spirometer. Recent data 
collected in patients with IPF demonstrate the feasi-
bility of asking patients to perform daily or weekly 
FVC measurements.35 36 Results from Russell et al 
suggest that daily FVC measurements correlated well 
with measurements recorded during clinic visits, and 
daily readings correlated with mortality over 3, 6 and 
12 months.35 Weekly FVC measurements over 24 weeks 
have been found to result in enhanced precision and 
power compared with FVC measurements taken in 
clinic on Weeks 1 and 24.36 Furthermore, previous 
studies of pirfenidone in IPF have demonstrated a 
treatment effect within a 24-week timeframe.37
The analysis of the primary endpoint in this study 
will be via a linear regression model of individual FVC 
measurements made each day over the 24-week treat-
ment period. It is acknowledged that daily measure-
ments of FVC can be considered as dependent 
measurements and that a mixed-effects model may 
be more appropriate. Indeed, a mixed-effects model 
will be conducted as a sensitivity analysis. However, 
the appropriate methods available to calculate sample 
size and the power for such a model require assump-
tions on the correlation structure across all patients 
and observations a priori and this information is not 
available. Therefore, a simple linear regression model 
without assumptions on the aforementioned correla-
tion structure was considered more appropriate for the 
purpose of sample size and power calculation. Further-
more, FVC decline will not be linear in every patient, as 
demonstrated by Russell et al.35 However, in the absence 
of any specific non-linear models for FVC decline over 
time, it was determined that a linear model was appro-
priate for this analysis.
Certain biomarkers, such as chemokine ligand 18 
(CCL18), matrix-metalloproteinase 7 (MMP7), chemo-
kine ligand 13 (CXCL13), cartilage oligomeric matrix 
protein (COMP), plasma surfactant protein-D and oste-
opontin, are differentially expressed in other fibrotic 
lung diseases38–42 and thus could be used to potentially 
distinguish subtypes of uILD. Therefore, samples will 
be collected during this study to allow an exploratory 
assessment of biomarkers in uILD. The exploratory 
biomarker analysis will aim to identify any biomarkers 
that change as a result of pirfenidone therapy or 
could be used to predict response to pirfenidone. In 
addition, the analysis will aim to identify protein or 
RNA biomarkers which are related to disease progres-
sion. Study participants will also be given the option 
to provide samples for DNA extraction at baseline to 
enable investigation of genetic polymorphisms and 
their potential role in the pathogenesis and associated 
clinical outcomes of uILD.
summary
This randomised, controlled phase II trial of the effi-
cacy and safety of pirfenidone in patients with fibrosing 
uILD, including those who meet proposed research 
criteria for IPAF, will be the first controlled study 
assessing a potential treatment option in this popu-
lation. The study design has considered a number of 
methodological factors, including the definition of 
uILD, current treatment practice in uILD and the most 
appropriate measurements of treatment efficacy in 
this population. It is hoped that these methodological 
considerations will allow meaningful clinical data to be 
generated that would inform treatment strategies for 
fibrotic uILD and thereby improve patient outcomes.
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